Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Louis Plzak

Urology Beaufort, SC Medical Doctor

NPI 1881768430 CMS profile 266405

1055 Ribaut Rd, Suite 10, Beaufort, SC 29902

Open in the dashboard

General payments

$4,824

115 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Louis Plzak of Beaufort, SC is reported in the CMS Open Payments database as having received $4,824 across 115 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 64th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $69 1
2024 General $2,377 6
2023 General $554 27
2022 General $589 26
2021 General $465 21
2020 General $147 6
2019 General $623 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Louis Plzak
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Louis Plzak were reported at $69. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Louis Plzak Urology median Middle half National median
2019 $623 $480 $147–$1,201 $163
2020 $147 $246 $87–$645 $114
2021 $465 $358 $111–$1,000 $132
2022 $589 $476 $143–$1,263 $149
2023 $554 $560 $168–$1,461 $160
2024 $2,377 $563 $170–$1,464 $164
2025 $69 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Olympus America Inc. $2,120 1 payment
  2. Teleflex LLC $450 12 payments
  3. Astellas Pharma US Inc $316 11 payments
  4. Boston Scientific Corporation $268 9 payments
  5. PROCEPT BioRobotics Corporation $190 3 payments
  6. Coloplast Corp $170 9 payments
  7. NeoTract Inc. $135 3 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $127 8 payments
  9. Sumitomo Pharma America, Inc. $104 5 payments
  10. Myovant Sciences Inc. $84 4 payments
  11. Other $860 50 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,580 111 payments
  2. Debt forgiveness $2,120 1 payment
  3. Education $109 2 payments
  4. Travel and Lodging $15 1 payment
Products named General payments · program years 2019–2025
  1. CYSTO-NEPHRO VIDEOSCOPE $2,120 1 payment
  2. UROLIFT $371 11 payments
  3. MYRBETRIQ $207 9 payments
  4. UroLift System $174 3 payments
  5. GEMTESA $133 7 payments
  6. Xofigo $127 8 payments
  7. rezum Generator $123 1 payment
  8. ORGOVYX $104 5 payments
  9. AQUABEAM SYSTEM $100 1 payment
  10. Nubeqa $97 6 payments
  11. Other $1,365 74 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

1,482

Median for Urology: 1,053

Drug cost

$159,593

Median for Urology: $101,464

Branded share of claims

16.1%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 65 $61,191
Eligard Leuprolide Acetate Brand 18 $32,953
Gemtesa Vibegron Brand 30 $27,307
Dutasteride Generic 493 $18,415
Tadalafil Generic 97 $6,563
Estradiol Generic 72 $4,530
Tamsulosin Hcl Generic 194 $4,502
Finasteride Generic 53 $911
Doxycycline Hyclate Generic 40 $584
Bicalutamide Generic 15 $503

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 67 billing codes

Paid by Medicare

$241,388

Of which drugs: $5,850

Medicare patients

1,130

Average age 76

Services billed

3,780

335 women, 795 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 29%
Ischemic heart disease 29%
Chronic kidney disease 28%
Cancer 26%
Atrial fibrillation 22%
COPD 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

115 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record